180 related articles for article (PubMed ID: 25963312)
21. Antidepressant drugs can modify cytotoxic action of temozolomide.
Bielecka AM; Obuchowicz E
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 27480195
[TBL] [Abstract][Full Text] [Related]
22. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
23. High-grade glioma in children and adolescents: a single-center experience.
Yazici G; Zorlu F; Cengiz M; Ozyigit G; Eren G; Yüce D; Varan A; Akyuz C; Akalan N; Gurkaynak M
Childs Nerv Syst; 2016 Feb; 32(2):291-7. PubMed ID: 26679932
[TBL] [Abstract][Full Text] [Related]
24. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
25. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Gokturk D; Kelebek H; Ceylan S; Yilmaz DM
Turk Neurosurg; 2018; 28(1):13-18. PubMed ID: 28191621
[TBL] [Abstract][Full Text] [Related]
28. Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
Giussani P; Bassi R; Anelli V; Brioschi L; De Zen F; Riccitelli E; Caroli M; Campanella R; Gaini SM; Viani P; Riboni L
Cancer Invest; 2012 Jan; 30(1):27-37. PubMed ID: 22236187
[TBL] [Abstract][Full Text] [Related]
29. Sensitizer drugs for the treatment of temozolomide-resistant glioblastoma.
Baritchii A; Jurj A; Soritau O; Tomuleasa C; Raduly L; Zanoaga O; Cernea D; Braicu C; Neagoe I; Stefan Florian I
J BUON; 2016; 21(1):199-207. PubMed ID: 27061549
[TBL] [Abstract][Full Text] [Related]
30. [Temozolomide, an oral chemotherapeutic agent with potential severe toxicity].
Soetekouw PM; Gijtenbeek JM; van der Maazen RW; Kappelle AC; van Herpen CM
Ned Tijdschr Geneeskd; 2007 Jan; 151(4):253-7. PubMed ID: 17323884
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Karpel-Massler G; Kast RE; Westhoff MA; Dwucet A; Welscher N; Nonnenmacher L; Hlavac M; Siegelin MD; Wirtz CR; Debatin KM; Halatsch ME
J Neurooncol; 2015 Mar; 122(1):21-33. PubMed ID: 25524815
[TBL] [Abstract][Full Text] [Related]
32. Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Azzalin A; Nato G; Parmigiani E; Garello F; Buffo A; Magrassi L
Neoplasia; 2017 Apr; 19(4):364-373. PubMed ID: 28319810
[TBL] [Abstract][Full Text] [Related]
33. Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Kerschbaumer J; Freyschlag CF; Bauer R; Obwegeser AA; Schubert GA; Thomé C; Seiz M
Anticancer Res; 2012 Dec; 32(12):5515-9. PubMed ID: 23225460
[TBL] [Abstract][Full Text] [Related]
34. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Khasraw M; Lee A; McCowatt S; Kerestes Z; Buyse ME; Back M; Kichenadasse G; Ackland S; Wheeler H
J Neurooncol; 2016 May; 128(1):163-171. PubMed ID: 26935578
[TBL] [Abstract][Full Text] [Related]
35. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Hainsworth JD; Ervin T; Friedman E; Priego V; Murphy PB; Clark BL; Lamar RE
Cancer; 2010 Aug; 116(15):3663-9. PubMed ID: 20564147
[TBL] [Abstract][Full Text] [Related]
36. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
[TBL] [Abstract][Full Text] [Related]
38. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
[TBL] [Abstract][Full Text] [Related]
39. Drug Repositioning in Oncology.
Serafin MB; Bottega A; da Rosa TF; Machado CS; Foletto VS; Coelho SS; da Mota AD; Hörner R
Am J Ther; 2021 Jan-Feb 01; 28(1):e111-e117. PubMed ID: 31033488
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J
J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
